Recombinant Human Transmembrane protein PVRIG (PVRIG)

What is the structural composition of human PVRIG and what functional domains are critical for research applications?

Human PVRIG is a single transmembrane protein of approximately 34 kDa comprising a single extracellular IgV domain, one transmembrane domain, and a long intracellular domain. The intracellular portion contains two tyrosine residues, with one positioned within an ITIM-like motif that potentially serves as a docking site for phosphatases . For research applications, the extracellular domain (typically spanning Thr41 & Glu43-Leu172) is most commonly used in recombinant protein constructs . The IgV domain is critical for PVRL2 (Nectin-2/CD112) binding and subsequent inhibitory signaling.

When designing experiments with recombinant PVRIG proteins, researchers should consider whether their research questions require:

• Full-length protein with transmembrane and intracellular domains

• Extracellular domain only (more common for binding studies)

• Fc-chimera constructs (improving stability and detection capabilities)

How does PVRIG interact with its binding partners and what methodologies can verify these interactions?

PVRIG functions primarily as a receptor for Nectin-2/CD112, a cell surface protein widely expressed on antigen-presenting cells and tumor cells . Evidence suggests PVRIG has the highest binding affinity for PVRL2 compared to other receptors in this network, such as TIGIT . PVRIG competes with CD226 (DNAM-1) for binding to PVRL2, creating a balanced system of inhibitory and activating signals .

To verify and characterize these interactions, researchers can employ:

• Cell-based binding assays: Using flow cytometry with PVRIG-overexpressing GS-CHO cells. For example, human PVRIG-overexpressing cells can be incubated with serially diluted antibodies followed by staining with PE-conjugated anti-human IgG Fc antibody .

• Protein-protein interaction assays: Immobilized human Nectin-2 with His Tag (at 5 μg/mL, 100 μL/well) can bind to recombinant PVRIG with a detectable linear range of 2-31 ng/mL .

• Blocking studies: Pre-incubating PVRIG-expressing cells with anti-PVRIG antibodies before adding PVRL2-Fc can demonstrate interference with the PVRIG-PVRL2 interaction .

What is the expression pattern of PVRIG across immune cell subsets, and how can researchers accurately measure this expression?

PVRIG is preferentially expressed in lymphocytes, particularly T cells and NK cells, but not in monocyte-derived dendritic cells . Expression patterns vary significantly between resting and activated states:

• In resting PBMCs, PVRIG expression is generally low

• Upon activation, PVRIG expression increases, with peak expression observed at later timepoints (around day 11) compared to other checkpoint receptors like TIGIT (which peaks earlier, around day 3)

• PVRIG is expressed on activated NK cells and T cells, especially on cytotoxic lymphocytes, while maintaining low expression on Treg cells

For accurate measurement of PVRIG expression, researchers should:

• Use flow cytometry with validated anti-PVRIG antibodies

• Include appropriate isotype controls and calculate fold expression by dividing the MFI of target by the MFI of isotype control

• Examine expression across multiple timepoints post-activation (24 hours, 3 days, 6 days, and 10 days) to capture dynamic changes

• Consider both surface staining (with anti-PVRIG PE) and intracellular staining (requiring fixation and permeabilization followed by anti-PVRIG Alexa Fluor 647)

How is PVRIG expression regulated during T cell activation, and what methodological approaches can track this dynamic process?

PVRIG expression shows distinct kinetics during T cell activation compared to other checkpoint receptors. While TIGIT expression peaks early (around day 3), PVRIG expression peaks later (approximately day 11) during the activation process . This temporal difference suggests distinct regulatory mechanisms and functional roles during T cell responses.

Methodological approaches to track PVRIG expression during activation include:

• Time-course analysis: Stimulate PBMCs with DynabeadsTM human T-activator CD3/CD28 and recombinant human IL-15 protein, then collect cells at specific timepoints (24h, 3 days, 6 days, 10 days) for flow cytometric analysis .

• Multi-parameter flow cytometry: Simultaneously assess PVRIG alongside other checkpoint receptors (TIGIT, PD-1, TIM3, LAG3) and activation markers to establish correlation patterns .

• Receptor internalization assays: Stain cells with anti-PVRIG at 4°C, then incubate at 37°C and measure remaining surface antibody at various timepoints using secondary anti-human IgG4 antibody detection .

What are the optimal conditions for evaluating PVRIG blockade in T cell functional assays?

When designing experiments to evaluate PVRIG blockade effects on T cell function, researchers should consider the following methodological approaches:

• Cell selection: Use antigen-specific CD8+ T cells (e.g., pp65-specific T cells) that have been activated for an appropriate duration to ensure PVRIG expression. Day 11 activated T cells show optimal PVRIG expression levels for blockade studies .

• Target cell selection: Choose cancer cell lines that express PVRL2, such as Mel-624 or Panc.05.04. Confirm PVRL2 expression by flow cytometry before experiments .

• Antibody concentration: Use anti-PVRIG antibodies at 5 μg/mL final concentration, with appropriate isotype controls at matching concentrations .

• Readout parameters: Measure multiple functional outcomes:

  • Cytokine production (IFNγ, TNFα)

  • Proliferation

  • Cytotoxicity (using luciferase-expressing target cells)

• Controls and combinations: Include:

  • Isotype control antibodies

  • Blockade of other checkpoint receptors (TIGIT, PD-1) for comparison

  • Combination treatments to assess synergistic effects

Variability in response to PVRIG blockade correlates with the level of PVRIG expression on T cells, so researchers should consider quantifying PVRIG levels on their effector cells before and during experiments .

What methods can be used to generate and validate high-quality recombinant PVRIG proteins for research applications?

Generation of high-quality recombinant PVRIG proteins for research requires careful consideration of several factors:

• Expression construct design:

  • Focus on the extracellular domain (typically Thr41 & Glu43-Leu172)

  • Consider fusion partners (e.g., Fc chimera) to enhance stability and facilitate detection

  • Include appropriate purification tags (e.g., His-tag)

• Expression systems:

  • HEK293 cells are commonly used for mammalian expression with proper glycosylation

  • CHO cells may be used as an alternative mammalian system

• Purification approach:

  • Implement multi-step purification to achieve >90% purity

  • Ensure endotoxin levels remain below 1 EU/μg for functional studies

• Validation methods:

  • SDS-PAGE analysis: Evaluate under both reducing and non-reducing conditions to assess purity and potential aggregation

  • Binding assays: Confirm functionality through binding to PVRL2/Nectin-2 (e.g., using immobilized human Nectin-2 with a linear detection range of 2-31 ng/mL)

  • Bioactivity testing: Verify inhibitory function in T cell activation assays

Researchers should document protein characteristics using both reducing and non-reducing SDS-PAGE conditions, as shown in commercial preparations where distinct banding patterns help confirm proper folding and disulfide bond formation .

How does PVRIG contribute to the immune checkpoint network in tumor microenvironments, and what experimental approaches best elucidate these interactions?

PVRIG functions within a complex network of inhibitory and stimulatory receptors in the tumor microenvironment. It is part of the nectin/nectin-like family of checkpoint receptors that includes TIGIT and CD96, which interact with ligands PVR and PVRL2 (Nectin-2) .

Key features of PVRIG in this network:

• PVRIG predominantly binds to PVRL2 with higher affinity than other receptors in the network

• PVRL2 is highly expressed in multiple cancer types and associated with poor survival

• PVRIG competes with the co-activating receptor DNAM-1 for PVRL2 binding

• PVRIG shows different expression kinetics and patterns compared to TIGIT, suggesting non-redundant functions

Experimental approaches to elucidate these interactions include:

• TCGA data analysis: Examine PVRL2:PVR ratio across cancer types by analyzing RNA expression values. This can be performed by dividing PVRL2 by PVR RNA Reads Per Kilobase Million values .

• Immunohistochemistry assessment: Evaluate PVRL2 expression in tumor tissues using antibodies like anti-PVRL2 (Sigma HPA-012759) and scoring based on intensity and prevalence of membranous staining:

  • Score 0: no staining

  • Score 1: weak staining in <50% of cells

  • Score 2: intense staining in <50% of cells or weak staining in >50% of cells

  • Score 3: intense staining in >50% of cells

• Competitive binding studies: Assess the hierarchical binding of different receptors (PVRIG, TIGIT, DNAM-1) to shared ligands using recombinant proteins and cell-based assays .

• Combination blockade experiments: Compare effects of blocking PVRIG alone versus combined blockade with other checkpoint receptors (TIGIT, PD-1) on T cell activation and tumor cell killing .

What are the functional consequences of PVRIG blockade on different lymphocyte subsets in anti-tumor immunity?

PVRIG blockade has distinct effects on different lymphocyte populations involved in anti-tumor immunity. Understanding these differential effects is crucial for developing effective immunotherapeutic strategies.

Effects on CD8+ T cells:

• Enhances antigen-specific cytokine production (IFNγ, TNFα)

• Increases cytotoxic activity against tumor cells expressing PVRL2

• The magnitude of enhancement correlates with PVRIG expression levels on T cells

Effects on NK cells:

• Augments NK cell cytotoxicity against tumor targets

• May influence antibody-dependent cellular cytotoxicity (ADCC) when using Fc-competent anti-PVRIG antibodies

Methodological approaches to assess these effects include:

• Cytokine production assays: Co-culture antigen-specific T cells with peptide-pulsed tumor cells expressing PVRL2 in the presence of anti-PVRIG or control antibodies. Measure cytokine levels by ELISA or intracellular cytokine staining .

• Multi-parameter flow cytometry: Assess changes in multiple checkpoint receptors (PVRIG, TIGIT, PD-1, TIM3, LAG3) following blockade to understand compensatory mechanisms .

How do PVRIG-targeted antibodies with different Fc functionalities compare in their mechanisms of action and therapeutic potential?

Anti-PVRIG antibodies can be engineered with different Fc regions that significantly impact their mechanisms of action and potential therapeutic efficacy. Comparing Fc-competent (e.g., IgG1) versus Fc-silent (e.g., IgG4) antibodies reveals important functional differences:

Fc-competent anti-PVRIG antibodies (e.g., IBI352g4a, IgG1):

• Can engage FcγR-expressing cells, potentially enabling additional effector mechanisms

• May deplete PVRIG-expressing cells through antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC)

• Could provide enhanced anti-tumor activity through multiple mechanisms beyond simple PVRIG blockade

Fc-silent anti-PVRIG antibodies (e.g., COM701, IgG4):

• Function primarily through disruption of PVRIG-PVRL2 interactions

• Minimize the risk of depleting activated T cells or NK cells that express PVRIG

• Focus on reversing T cell exhaustion rather than eliminating immune cells

Methodological approaches to compare these antibodies include:

• Antibody generation and characterization:

  • Humanize murine antibodies by replacing framework regions with homologous human germline IgG sequences

  • Express in HEK293 cells with either transient or stable expression systems

  • Purify and confirm binding properties through cell-based binding assays using PVRIG-overexpressing cell lines

• Comparative functional assays:

  • Direct binding competition to compare affinity for PVRIG

  • Blockade of PVRIG-PVRL2 interaction efficacy

  • ADCC/CDC assays with different effector cells

  • T cell functional recovery in exhaustion models

• Preclinical models:

  • Humanized mouse models

  • Patient-derived xenograft models

  • Ex vivo studies with patient samples

What potential biomarkers could predict response to PVRIG-targeted therapies, and how can researchers systematically identify and validate them?

Identifying biomarkers to predict response to PVRIG-targeted therapies is a critical area for advancing this immunotherapeutic approach. Several potential biomarkers warrant investigation:

• PVRIG expression levels on TILs:

  • Higher PVRIG expression on tumor-infiltrating lymphocytes may correlate with greater response to blockade

  • The magnitude of effect from PVRIG blockade relates to PVRIG expression levels

• PVRL2 (Nectin-2) expression in tumors:

  • PVRL2 is highly expressed in multiple cancer types

  • The PVRL2:PVR ratio may be informative for predicting which cancers might respond better to PVRIG versus TIGIT blockade

• PVRIG/TIGIT co-expression patterns:

  • Differential expression kinetics (TIGIT peaking early, PVRIG later) suggests temporal considerations for therapeutic targeting

  • Co-expression may identify tumors where combination blockade would be most effective

• T cell exhaustion signatures:

  • Expression of multiple checkpoint receptors (PD-1, TIM3, LAG3) alongside PVRIG

  • T-bet and Eomes transcription factor expression patterns

Methodological approaches for biomarker discovery and validation:

• Multi-parameter flow cytometry:

  • Characterize PVRIG expression alongside other inhibitory receptors in different immune cell subsets from tumor samples

  • Correlate baseline expression with functional responses to blockade ex vivo

• Transcriptomic analysis:

  • Analyze TCGA data to identify gene expression patterns associated with PVRIG pathway activation

  • Develop gene signatures that correlate with response in preclinical models

• Immunohistochemistry approaches:

  • Develop standardized IHC protocols for PVRIG and PVRL2

  • Use scoring systems (0-3) based on staining intensity and prevalence

• Functional biomarker assays:

  • Measure PVRIG internalization rates upon antibody binding

  • Assess baseline PVRIG-PVRL2 binding in patient samples and correlation with clinical outcomes

What are the key quality control parameters for recombinant PVRIG proteins, and how do they impact experimental outcomes?

Quality control of recombinant PVRIG proteins is essential for ensuring reliable and reproducible experimental results. Researchers should consider these critical parameters:

• Purity assessment:

  • Aim for >90% purity as determined by SDS-PAGE analysis

  • Evaluate under both reducing and non-reducing conditions to assess proper folding and disulfide bond formation

  • Contaminants can lead to non-specific effects or inconsistent binding properties

• Endotoxin levels:

  • Maintain endotoxin levels below 1 EU/μg for functional studies

  • Higher endotoxin can confound immunological assays by non-specifically activating immune cells

• Functional validation:

  • Confirm binding to PVRL2 with defined affinity parameters

  • Established binding assays should show linear detection ranges (e.g., 2-31 ng/mL for PVRIG binding to immobilized Nectin-2)

• Stability assessment:

  • Monitor protein stability under various storage conditions

  • Evaluate freeze-thaw stability and potential for aggregation

  • Consider using stabilization approaches (e.g., Fc-fusion partners) for improved handling

Methodological approaches for quality control include:

• Analytical SEC (Size Exclusion Chromatography):

  • Assess monomer content versus aggregates

  • Monitor batch-to-batch consistency

• Binding kinetics analysis:

  • Use surface plasmon resonance (SPR) to determine kon and koff rates

  • Compare affinity constants (KD) between different protein preparations

• Thermal stability analysis:

  • Differential scanning fluorimetry to determine melting temperatures

  • Identify stabilizing buffer conditions

What are the most common technical challenges when working with recombinant PVRIG in immunological assays, and how can they be addressed?

Researchers working with recombinant PVRIG in immunological assays may encounter several technical challenges that can impact experimental outcomes:

• Variable expression levels across donor samples:

  • Challenge: PVRIG expression varies significantly between donors and activation states

  • Solution: Screen multiple donors, document PVRIG expression levels before experiments, and normalize results to expression levels

• Receptor internalization effects:

  • Challenge: PVRIG can be internalized upon antibody binding, complicating surface detection and functional studies

  • Solution: Implement internalization assays to track receptor dynamics, using staining at 4°C followed by incubation at 37°C to monitor surface retention over time

• Competition with other receptors for ligand binding:

  • Challenge: PVRL2 interacts with multiple receptors (PVRIG, TIGIT, DNAM-1) with different affinities

  • Solution: Use controlled blocking experiments with specific antibodies against each receptor to delineate individual contributions

• Fc-mediated effects in blocking experiments:

  • Challenge: Antibody Fc regions can engage Fc receptors, confounding interpretation of blocking effects

  • Solution: Include appropriate isotype controls and consider using F(ab')2 fragments to eliminate Fc-mediated effects

• Establishing physiologically relevant assay conditions:

  • Challenge: In vitro conditions may not recapitulate the complex tumor microenvironment

  • Solution: Use co-culture systems with multiple cell types, consider 3D culture models, and validate findings in ex vivo systems with patient samples

Addressing these challenges requires careful experimental design and appropriate controls:

• Standardized activation protocols:

  • Use consistent T cell activation approaches (e.g., CD3/CD28 Dynabeads plus IL-15)

  • Document activation markers alongside PVRIG expression

• Multiplexed readouts:

  • Measure multiple functional parameters (cytokine production, proliferation, cytotoxicity)

  • Correlate functional outcomes with receptor expression levels

• Extended time-course studies:

  • Account for the delayed peak expression of PVRIG (day 11) compared to other checkpoints

  • Design experiments to capture both early and late effects of PVRIG blockade